SK285969B6 - Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek - Google Patents

Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek Download PDF

Info

Publication number
SK285969B6
SK285969B6 SK1122-99A SK112299A SK285969B6 SK 285969 B6 SK285969 B6 SK 285969B6 SK 112299 A SK112299 A SK 112299A SK 285969 B6 SK285969 B6 SK 285969B6
Authority
SK
Slovakia
Prior art keywords
cells
tumor
nucleic acid
tumor suppressor
protein
Prior art date
Application number
SK1122-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK112299A3 (en
Inventor
Loretta Nielsen
Jo Ann Horowitz
Daniel C. Maneval
G. William Demers
Mary Ellen Rybak
Gene Resnick
Original Assignee
Canji, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji, Inc. filed Critical Canji, Inc.
Publication of SK112299A3 publication Critical patent/SK112299A3/sk
Publication of SK285969B6 publication Critical patent/SK285969B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
SK1122-99A 1997-02-18 1998-02-17 Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek SK285969B6 (sk)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US3806597P 1997-02-18 1997-02-18
US80168197A 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US80175597A 1997-02-18 1997-02-18
US80176597A 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28
PCT/US1998/003514 WO1998035554A2 (en) 1997-02-18 1998-02-17 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Publications (2)

Publication Number Publication Date
SK112299A3 SK112299A3 (en) 2000-12-11
SK285969B6 true SK285969B6 (sk) 2007-12-06

Family

ID=27556335

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1122-99A SK285969B6 (sk) 1997-02-18 1998-02-17 Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek

Country Status (19)

Country Link
EP (1) EP0969720B1 (ko)
JP (1) JP2001511815A (ko)
KR (2) KR100620939B1 (ko)
CN (1) CN1248731C (ko)
AT (1) ATE361668T1 (ko)
AU (1) AU737621B2 (ko)
BR (1) BR9807418A (ko)
CA (1) CA2282683A1 (ko)
CZ (1) CZ298488B6 (ko)
DE (1) DE69837754T2 (ko)
ES (1) ES2287974T3 (ko)
HK (1) HK1026579A1 (ko)
HU (1) HUP0004326A3 (ko)
IL (2) IL131447A0 (ko)
NO (1) NO993943L (ko)
NZ (1) NZ337283A (ko)
PL (1) PL193767B1 (ko)
SK (1) SK285969B6 (ko)
WO (1) WO1998035554A2 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
CN1203632A (zh) 1995-07-17 1998-12-30 德克萨斯州立大学董事会 P16表达构建物及其在癌治疗中的应用
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ATE550429T1 (de) 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
MY137303A (en) * 1997-12-22 2009-01-30 Schering Corp Methods for treating proliferative diseases
CA2325561A1 (en) * 1998-04-22 1999-10-28 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000056351A2 (en) * 1999-03-19 2000-09-28 Schering Corporation Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
EP2241887B1 (en) * 2000-11-27 2015-01-14 Minerva Biotechnologies Corporation Diagnostics, drug screening and treatment for cancer
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
JPWO2005061001A1 (ja) * 2003-12-24 2007-07-12 株式会社ロコモジェン 癌の抑制方法
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN106692989A (zh) * 2017-03-07 2017-05-24 大连民族大学 一种药物脂质体/p53基因复合物及其制备方法和应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
ATE210653T1 (de) * 1993-10-15 2001-12-15 Schering Corp Tricyclische sulfonamide-derivate zur inhibierung der g-protein funktion und fur die bekandlung von proliferativen erkrantungen
WO1997023478A1 (en) * 1995-12-22 1997-07-03 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases

Also Published As

Publication number Publication date
HK1026579A1 (en) 2000-12-22
NO993943D0 (no) 1999-08-17
JP2001511815A (ja) 2001-08-14
CN1248731C (zh) 2006-04-05
EP0969720A2 (en) 2000-01-12
EP0969720B1 (en) 2007-05-09
SK112299A3 (en) 2000-12-11
DE69837754D1 (de) 2007-06-21
CZ298488B6 (cs) 2007-10-17
HUP0004326A2 (hu) 2001-02-28
NO993943L (no) 1999-10-15
IL195605A0 (en) 2011-08-01
KR100620939B1 (ko) 2006-09-06
PL193767B1 (pl) 2007-03-30
CZ293399A3 (cs) 2000-03-15
EP0969720A4 (en) 2004-05-12
IL131447A0 (en) 2001-01-28
CN1252689A (zh) 2000-05-10
DE69837754T2 (de) 2008-02-07
WO1998035554A2 (en) 1998-08-20
ES2287974T3 (es) 2007-12-16
AU737621B2 (en) 2001-08-23
KR100688409B1 (ko) 2007-03-02
WO1998035554A3 (en) 1998-11-26
KR20000071185A (ko) 2000-11-25
HUP0004326A3 (en) 2003-07-28
PL335334A1 (en) 2000-04-25
KR20050113287A (ko) 2005-12-01
AU6438098A (en) 1998-09-08
NZ337283A (en) 2001-02-23
CA2282683A1 (en) 1998-08-20
ATE361668T1 (de) 2007-06-15
BR9807418A (pt) 2002-01-22

Similar Documents

Publication Publication Date Title
US7157079B2 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
SK285969B6 (sk) Prípravky na liečenie cicavčích nádorových alebo hyperproliferatívnych buniek
Galbiati et al. Caveolin-1 expression negatively regulates cell cycle progression by inducing G0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism
US20020048566A1 (en) Modulation of cellular apoptosis and methods for treating cancer
JP2003277272A (ja) ＤＮＡ損傷剤およびр５３を含有する組成物
US20070293453A1 (en) Combinatorial Methods For Inducing Cancer Cell Death
US20080286239A1 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US6197754B1 (en) Suppression of tumor growth by a mini-E1A gene
Sasaki et al. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells
EP0910357B1 (en) Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression
JP2015057394A (ja) 癌治療感作物質
KR101163248B1 (ko) 인터페론 내성 종양의 치료를 위한 방법 및 조성물
KR100739118B1 (ko) Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자의 신규한 용도
US20010044420A1 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US20090233848A1 (en) Pea15 as a Tumor Suppressor Gene
MXPA99007571A (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20020169126A1 (en) Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
Azab Approaches for Enhancing Therapeutic Efficacy of a Novel IL-10 Gene Family Member: MDA-7/IL-24
Bartholomeusz Mechanism of anti-tumor activity of adenovirus type 5 E1A in ovarian cancer
WO2000056351A2 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20100217